During pregnancy and the disease-modifying treatment (DMT)-free postpartum period, serum neurofilament-light (sNfL) levels were augmented [1]. This increase was independent of relapses, suggesting increased subclinical disease activity during this time span. Women on DMT had lower NfL during pregnancy. sNfL may qualify as a sensitive and minimally-invasive measure of disease activity during pregnancy.

These were the main results of a study that was presented as late-breaking abstract. Dr Özgür Yaldizli (University Hospital Basel, Switzerland) explained the study’s various objectives: to describe DMT use before, during, and after pregnancy in the Swiss MS cohort study (SMCS); to assess the potential of sNfL as a marker of disease activity during and after pregnancy; and to evaluate whether interrupting DMT use due to pregnancy leads to increased NfL levels in MS.

A total of 72 pregnancies in 63 relapsing MS patients were evaluated; 13 early terminated pregnancies in 10 patients were excluded. Median age was 31.4 years; median disease duration 7.1 years; median Expanded Disability Status Scale (EDSS) score 1.5 at last visit before giving birth; and median follow-up 6 years. Of 433 included samples, 167 were taken before pregnancy, 92 during pregnancy/DMT-free postpartum, and 174 after pregnancy. Most patients (n=39) were treated with fingolimod or natalizumab as last medication before giving birth; 4 patients used no DMT before, during, and after pregnancy. In 14 of 72 pregnancies, women were exposed to DMT >6 months during pregnancy (6 rituximab/ocrelizumab, 4 natalizumab, 1 interferon-beta 1a, 1 fingolimod, and 1 glatiramer acetate). In 39 pregnancies, women were exposed to DMT in the first two trimesters; in 15 pregnancies, women discontinued treatment before getting pregnant.

Relapses were more likely in the first trimester and the first 3 months postpartum. NfL levels increased towards the last trimester and in the first 3 months postpartum, not only in women who relapsed. Mean NfL levels were 22% higher during pregnancy (β=1.22; P<0.001). During the postpartum, 29 relapses occurred. Relapses were associated with 98% higher NfL levels (β=1.98; P<0.001). Mean NfL was 13% higher during the postpartum (β=1.13; P=0.009). However, this difference lost significance after including DMT exposure into the model (β=1.07; P=0.178), indicating that women on DMT had lower NfL during pregnancy. Dr Yaldizli concluded that strategies allowing to continue DMT during pregnancy may be warranted.

 

  1. Yaldizli Ö. MSVIRTUAL2020, Abstract LB01.06.

Author